1. Home
  2. SOWG vs CRDF Comparison

SOWG vs CRDF Comparison

Compare SOWG & CRDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Sow Good Inc.

SOWG

Sow Good Inc.

N/A

Current Price

$2.31

Market Cap

69.9M

ML Signal

N/A

Logo Cardiff Oncology Inc.

CRDF

Cardiff Oncology Inc.

N/A

Current Price

$0.89

Market Cap

82.5M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
SOWG
CRDF
Founded
2010
1999
Country
United States
United States
Employees
N/A
N/A
Industry
Packaged Foods
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
69.9M
82.5M
IPO Year
2011
2012

Fundamental Metrics

Financial Performance
Metric
SOWG
CRDF
Price
$2.31
$0.89
Analyst Decision
Buy
Analyst Count
0
6
Target Price
N/A
★ $6.28
AVG Volume (30 Days)
5.3K
★ 413.2K
Earning Date
11-13-2026
11-09-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 27.37
EPS
N/A
★ N/A
Revenue
N/A
★ $365,993.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$8.70
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
★ 49.61
52 Week Low
$0.10
$0.76
52 Week High
$15.90
$3.31

Technical Indicators

Market Signals
Indicator
SOWG
CRDF
Relative Strength Index (RSI) 46.28 38.18
Support Level $2.10 $0.76
Resistance Level $2.62 $1.13
Average True Range (ATR) 0.18 0.08
MACD 0.05 -0.00
Stochastic Oscillator 82.29 35.89

Price Performance

Historical Comparison
SOWG
CRDF

About SOWG Sow Good Inc.

Sow Good Inc is engaged in manufacturing and marketing freeze-dried fruits, vegetables, snacks, smoothies, and soups. The company also sells gluten-free products under the Sow Good brand. The company is developing a freeze-dried candy market and snack manufacturing to provide consumers with flavorful freeze-dried treats. The company operates in one reportable segment, reflecting its capital-light business model under which it earns proceeds from the sale of freeze-dried candy products.

About CRDF Cardiff Oncology Inc.

Cardiff Oncology Inc is a clinical-stage biotechnology company advancing cancer treatments focused on PLK1 inhibition, a validated oncology target with practice-changing potential. Its main asset, onvansertib, is a specific, oral PLK1 inhibitor currently being evaluated in a Phase 2 trial for first-line treatment of RAS-mutated metastatic colorectal cancer (mCRC), addressing a large, underserved patient population with high unmet need. Onvansertib is also under investigation in other PLK1-driven cancers through ongoing investigator-initiated trials and has shown robust single agent clinical activity in hard-to-treat tumors. By targeting tumor vulnerabilities, to overcome treatment resistance and deliver improved clinical outcomes for patients.

Share on Social Networks: